Why is COVID-19 more severe in men and elders? | UW Medicine

By UW Medicine | Newsroom

The immune system usually mounts a strong immune response to infection by SARS-CoV-2, the virus that causes COVID-19. That defensive response, however, appears to be weaker in men and people over the age of 60, a study led by researchers at the University of Washington School of Medicine in Seattle has found.

“There were some early studies that suggested that there was a fairly weak antiviral response shortly after infection, but we found a very robust immune response in patients at the time of symptom onset,” said lead author Nicole Lieberman. “But differences in the immune response in older individuals and men may contribute to the greater severity and higher mortality we see in these groups.”

Lieberman is a research scientist in the laboratory of Alex Greninger. He is an assistant professor in the department of Laboratory Medicine and Pathology at the University of Washington

Read More

AT CAGR of 12.13%, Translational Regenerative Medicine Market will Revenue to Cross USD 481.40 Million in 2020 to 2025

The MarketWatch News Department was not involved in the creation of this content.

Sep 01, 2020 (Heraldkeepers) —
Translational Regenerative MedicineMarket is valued at USD 216.00 Million in 2018 and expected to reach USD 481.40 Million by 2025 with the CAGR of 12.13% over the forecast period.

The latest report pertaining to Translational Regenerative Medicine Market provides a detailed analysis regarding market size, revenue estimations and growth rate of the industry. In addition, the report illustrates the major obstacles and newest growth strategies adopted by leading manufacturers who are a part of the competitive landscape of this market.

Get Sample Copy of This Premium Report @

*The sample pages of this report is immediately accessible on-demand.**

Market Analysis of Translational Regenerative Medicine –

Translational regenerative medicine very broad, new approach to medicine which uses the advances in stem cell technology. These medicines make the use of stem cell

Read More

New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema

CARLSBAD, Calif., Sept. 2, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced the publication today of the results from a compassionate-use study evaluating IONIS-PKKRx and IONIS-PKK-LRx in patients living with severe bradykinin-mediated angioedema in The New England Journal of Medicine (NEJM). IONIS-PKKRx and IONIS-PKK-LRx are investigational antisense medicines designed to reduce the production of prekallikrein, or PKK, which plays a key role in the activation of inflammatory mediators associated with acute attacks of hereditary angioedema (HAE). In the study, researchers found that the drugs reduced plasma prekallikrein activity levels and showed evidence of clinical efficacy in reducing the number of breakthrough attacks per month in patients over the course of the treatment, including complete resolution in a patient with Type 1 HAE. To view the published study, please visit

Hereditary angioedema is a rare autosomal dominant disease that results in recurrent, painful attacks

Read More

UPMC, University Of Pittsburgh School Of Medicine Citing Widely-Available COVID-19 Treatment

PITTSBURGH (KDKA) – UPMC and the University of Pittsburgh School of Medicine are citing evidence that there is a cheap and widely available option for some patients combatting COVID-19.

This study went so well, that the World Health Organization is recommending this drug be used worldwide.

They found people on a ventilator and oxygen should be given corticosteroids.

Researchers say it’s rare your able to find a drug where the evidence of the effectiveness in saving lives is so consistent.

It was the on trial in the country to test this drug.

Between March and June, the steroids trial was given to random adults in the ICU with Covid 19, this was done in 121 hospitals across 8 countries.

The trial found a 93% probability that the steroid would improve a patient’s outcome as opposed to not having the steroid.

The results looked to be consistent across age, race,

Read More

Navid Vahedi Discusses Fusion IV Pharmaceuticals INC and the Future of Medicine

Press release content. The AP news staff was not involved in its creation.

PRESS RELEASE: Paid content

Press release content. The AP news staff was not involved in its creation.

September 3, 2020 GMT

Los Angeles, CA – ( NewMediaWire ) – September 03, 2020 –  Dr. Navid Vahedi of Fusion IV Pharmaceuticals INC discusses his approach to medical treatment and the future of medicine in the modern world.

Dr. Navid Vahedi and Fusion IV Pharmaceuticals INC are well-known for their unconventional approach to medicine. Rather than adhering to all of the tenets of Western medicine, which often focus on minimizing symptoms, Dr. Vahedi believes in Functional Medicine. Functional Medicine attempts to treat patients by finding the source of their pain or illness and developing a treatment plan to eliminate the issue. 

Dr. Vahedi also uses this mentality at Fusion IV Pharmaceuticals INC,

Read More

Joe Biden and Kamala Harris Are ‘Completely Aligned’ On Socialized Medicine


Posted: Sep 04, 2020 12:01 AM

The opinions expressed by columnists are their own and do not necessarily represent the views of

Democrat vice presidential candidate Kamala Harris recently proclaimed that “Joe Biden and I are completely aligned” on having a government takeover of healthcare.

Biden has previously said that he is a “transition candidate,” effectively conceding that his presidency would be a stepping stone for his running mate’s radical progressive agenda. 

During her short-lived candidacy, Harris embraced a vowed socialist Bernie Sanders’ “Medicare for All” scheme, endorsing trillions of dollars in Sanders-style tax hikes on the American people. 

Harris would impose a new 7.5 percent payroll tax on employers, a $3.9 trillion tax hike that would slash wages for millions of middle class Americans as employers pass down the extra costs to their workers. Harris would also impose a 4 percent payroll tax hike on families making

Read More

Visiongain publishes Precision Medicine Market 2020-2030 report

LONDON, Aug. 27, 2020 /PRNewswire/ — Precision Medicine–our new study reveals trends, R&D progress, and predicted revenues

Where is the Precision Medicine market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 375 pages report provides 271 tables, 267 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Precision Medicine Market. See how to exploit the opportunities.

This Visiongain report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

Forecasts to 2030

Read More

Foundation Medicine wins FDA OK for pan-cancer liquid biopsy test

The Food and Drug Administration on Wednesday approved a comprehensive “liquid biopsy” platform that can detect multiple kinds of cancer and genomic alterations from pieces of tumor DNA circulating in a patient’s blood. The Foundation Medicine test, designed to identify specific types of cancer and match patients’ mutations to genetically targeted therapies, joins one approved earlier this month developed by Guardant Health.

The FDA has previously approved liquid biopsy tests for individual cancers and as so-called companion diagnostics, which identify whether patients are likely to benefit from a specific targeted drug. Foundation Medicine, a Cambridge, Mass., unit of Swiss biopharma Roche (RHBBY), has won the agency’s second nod for a pan-cancer blood assay, which combines liquid biopsy with other kinds of testing to find more diagnostic and genomic biomarkers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

Read More

Researchers argue health care systems should use ‘food as medicine’ interventions

health food
Credit: Pixabay/CC0 Public Domain

An analysis recently published in the British Medical Journal argues for increased implementation of “food is medicine” interventions in the health care system. The article was co-authored by Seth A. Berkowitz, MD, MPH, assistant professor of medicine at the UNC School of Medicine, who mostly recently argued in the New England Journal of Medicine that food insecurity is known to be a health equity issue that disproportionately affects racial/ethnic minorities and those with lower incomes and rural communities. Thus, food insecurity is now playing a big role in the COVID-19 pandemic and associated health outcomes.

Berkowitz has conducted a number of studies on health-related social needs and their effect on health outcomes, published in JAMA Internal Medicine.

Sarah Downer, JD, from the Center for Health Law and Policy Innovation at Harvard Law School is the first author of the BMJ study, along with Timothy Harlan,

Read More

Foundation Medicine’s cancer-profiling blood test approved by FDA

The FDA has approved Foundation Medicine’s liquid biopsy blood test, allowing oncologists to profile the genomic mutations found within any solid tumor without needing to remove and analyze small slices of tissue, and to help assign an individual cancer patient their most correct treatment.

The comprehensive FoundationOne Liquid CDx test returns reports on more than 300 alterations in cancer-related genes, as well as biomarkers such as tumor mutational burden and microsatellite instability to predict a person’s response to certain therapies.

“Many cancer patients are unable to have a tissue biopsy,” said Foundation Medicine co-founder Levi Garraway, who currently serves as chief medical officer and head of global product development at Roche, its corporate parent.

Fierce Biotech Webinar

Overcoming Scalability Challenges with Autologous Therapies

Catalent presents a clinical-to-commercial perspective on autologous therapies. Join experts Prof. Gerhard Bauer and Catalent’s Dr. James Crutchley as they discuss challenges and an innovative methodology to

Read More